Similar articles

• Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.

  Park JY, Park JS, Kim YC. Park JY, et al. Eur J Dermatol. 2012 Nov-Dec;22(6):811-2. doi: 10.1684/ejd.2012.1861. Eur J Dermatol. 2012. PMID: 23178879 No abstract available.
• Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.

  Kawano H, Suzuki T, Ishii S, Wakahashi K, Kawano Y, Sada A, Minagawa K, Ueno D, Yamasaki T, Itoh T, Yokozaki H, Katayama Y. Kawano H, et al. Eur J Haematol. 2014 Apr;92(4):362-4. doi: 10.1111/ejh.12249. Epub 2014 Jan 10. Eur J Haematol. 2014. PMID: 24341928 No abstract available.
• Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.

  Alencar C, Abramowtiz M, Parekh S, Braunshweig I, Jacobson M, Silverman L, Verma A. Alencar C, et al. Am J Hematol. 2009 Oct;84(10):688-9. doi: 10.1002/ajh.21510. Am J Hematol. 2009. PMID: 19722261 No abstract available.
• Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

  Steensma DP, Stone RM. Steensma DP, et al. Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. doi: 10.1016/j.hoc.2010.02.012. Hematol Oncol Clin North Am. 2010. PMID: 20359633 Review.
• FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

  Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. Kaminskas E, et al. Oncologist. 2005 Mar;10(3):176-82. doi: 10.1634/theoncologist.10-3-176. Oncologist. 2005. PMID: 15793220 Review.